Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature


Cite item

Full Text

Abstract

Diffuse large B-cell lymphoma is categorized by gene expression profiling into germinal center (GCB) and activated B-cell (ABC) subtype, also referred to as non-germinal center B-cell (non-GCB) by immunohistochemistry. ABC DLBCL is characterized by NF-κB pathway activation and high expression of IRF4/MUM1, a key transcription factor in B cell differentiation. Patients with ABC DLBCL have a significantly worse outcome when treated with standard chemotherapy (R-CHOP). Lenalidomide have shown activity in the ABC-DLBCL in combination with R-CHOP. But about 40% of patients remain resistant. We present the experience of treatment of a patient with generalized non-GCB-DLBCL using the intensive protocol R-mNHL-BFM-90 with lenalidomide.

About the authors

N G GABEEVA

National Research Center for Hematology, Russian Federation

Email: dr.gabeeva@gmail.com
к.м.н., н.с. ОИВХЛсКДС; тел.: 8(495)612-48-10, 8(905)722-61-95 (моб.) Moscow, Russia

E E ZVONKOV

National Research Center for Hematology, Russian Federation

д.м.н., зав. отд-нием ИВХЛсКДС Moscow, Russia

D A KOROLEVA

National Research Center for Hematology, Russian Federation

аспирант ОИВХЛсКДС Moscow, Russia

M M CHUKAVINA

National Research Center for Hematology, Russian Federation

ГБУЗ МО Коломенская ЦРБ Moscow, Russia

T N OBUKHOVA

National Research Center for Hematology, Russian Federation

к.м.н., зав. лаб. кариологии Moscow, Russia

A M KOVRIGINA

National Research Center for Hematology, Russian Federation

д.б.н., зав. лаб. патологической анатомии Moscow, Russia

References

  1. Swerdlow S.H, Campo E, Harris N.L, Jaffe E.S, Pileri S.A, Stein H, Thiele J, Vardiman J.W. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. IARC, Lyon, 2016.
  2. Alizadeh A.A, Eisen M.B, Davis R.E et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-11.
  3. Davis R.E, Brown K.D, Siebenlist U, Staudt L.M. Constitutive nuclear factor kappa B activity is required for survival of activated B Cell - like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194: 1861-74.
  4. Davis R.E, Ngo V.N, Lenz G, Tolar P, Young R.M, Romesser P.B, Kohlhammer H, Lamy L, Zhao H, Yang Y et al. Chronic active B-cell - receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463: 88-92.
  5. Compagno M, Lim W.K, Grunn A, Nandula S.V, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459: 717-721.
  6. Gaidano G, Carbone A. MUM1: a step ahead toward the understanding of lymphoma histogenesis. Leukemia. 2000 Apr; 14(4):563-6.
  7. Iqbal J, Greiner T.C, Patel K. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007 November; 21(11):2332-2343.
  8. Christine P. Hans, Dennis D. Weisenburger, Timothy C. Greiner, Randy D. Gascoyne, Jan Delabie, German Ott, H. Konrad Mu¨ller-Hermelink, Elias Campo, Rita M. Braziel, Elaine S. Jaffe, Zenggang Pan, Pedro Farinha, Lynette M. Smith, Brunangelo Falini, Alison H. Banham, Andreas Rosenwald, Louis M. Staudt, Joseph M. Connors, James O. Armitage, Wing C. Chan. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 (January); 103(1).
  9. Rosenwald A, Wright G, Chan W.C et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:1937-1947.
  10. Visco C, Yan Li, Xu-Monette Z.Y, Miranda R.N, Green T.M, Yong Li, Tzankov A, Wei Wen, Wei min Liu, Kahl B.S, E.S.G.d’ Amore ESGd´, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Youli Zu, Bhagat G, Winter J.N, Wang Huan-You, O’Neill S, C.H. Dunphy C.H, Hsi Eric D, Zhao X Frank, Go R.S, Choi W.W.L, Zhou Fan, Czader M, Jiefeng Tong, Xiaoying Zhao, van Krieken J Han, Qing Huang, Weiyun Ai, Joan Etzell, Ponzoni M, Ferreri A.J.M, Piris M.A, Møller M.B, Bueso-Ramos C.E, Medeiros L.J, Lin Wu, Young Ken H. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012 September; 26(9): 2103-2113.
  11. Магомедова А.У., Кравченко С.К., Кременецкая A.M., Звонков Е.Е., Барях Е.А., Мангасарова Я.К., Капланская И.Б., Самойлова Р.С., Воробьев И.А., Обухова Т.Н., Карагюлян С.Р., Шулутко Е.М., Галстян Г.М., Марьин Д.С., Габеева Н.Г., Воробьев А.И., Девятилетний опыт лечения больных диффузной В-крупноклеточной лимфосаркомой. Терапевтический архив. 2011; 83(7): 5-10.
  12. Звонков Е.Е, Морозова А.К, Кравченко С.К. Лечение взрослых больных первичной диффузной В-крупноклеточной лимфосаркомой желудка по модифицированной программе NHL-BFM-90. Программное лечение заболеваний системы крови / Под ред. В.Г. Савченко, академика РАН. М.: Практика, 2012; Т. II: 659-678.
  13. Магомедова А.У. Диффузная В-крупноклеточная лимфосаркома лимфоидных органов: клинические формы, лечение: дис. … д.м.н. М., 2008.
  14. Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni A.M. Prolonged survival in poor - risk diffuse large B-cell lymphoma following front - line treatment with rituximab - supplemented, early - intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007 Aug; 21(8):1802-11.
  15. Nowakowski G.S, La Plant B, Macon W.R, Reeder C.B, Foran J.M, Nelson G.D, Thompson C.A, Rivera C.E, Inwards D.J, Micallef I.N, Johnston P.B, Porrata L.F, Ansell S.M, Gascoyne R.D, Habermann T.M, Witzig T.E. Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cel Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. J Clin Oncol. 2015; 33:251-257.
  16. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9:105-116.
  17. Cunningham D, Hawkes E.A, Jack A et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013; 381:1817-1826.
  18. Delarue R, Tilly H, Mounier N et al. Dose - dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet Oncol. 2013; 14:525-533.
  19. Shipp M.A, Neuberg D, Janicek M et al. High - dose CHOP as initial therapy for patients with poor - prognosis aggressive non-Hodgkin’s lymphoma: A dose - finding pilot study. J Clin Oncol. 1995; 13:2916-2923.
  20. Wilson W.H, sin-Ho J, Pitcher B.N et al: Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303. Blood. 2016; 128(22): 469.
  21. Greb A, Bohlius J, Schiefer D et al. High - dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev. 2008 Jan 23; (1): CD004024.
  22. Patrick J, Stiff M.D, Joseph M, Unger PhD, James R, Cook M.D, Louis S. Constine M.D, Stephen Couban, Douglas A., Stewart M.D, Thomas C., Shea M.D, Pierluigi Porcu, Jane N., Winter M.D, Brad S. Kahl M.D, Thomas P. Miller M.D, Raymond R. Tubbs D.O, Deborah Marcellus, Jonathan W. Friedberg, Kevin P. Barton, Glenn M. Mills, M.D., Michael Le Blanc, Ph.D., Lisa M. Rimsza, M.D., Stephen J. Forman, M.D., and Richard I. Fisher, M.D. Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med. 2013; 369:1681-1690.
  23. Christian Récher, Bertrand Coiffi er, Corinne Haioun, Thierry Jo Molina, Christophe Fermé, Olivier Casasnovas, Catherine Thiéblemont, André Bosly,Guy Laurent, Franck Morschhauser, Hervé Ghesquières, Fabrice Jardin, Serge Bologna, Christophe Fruchart, Bernadette Corront, Jean Gabarre,Christophe Bonnet, Maud Janvier, Danielle Canioni, Jean-Philippe Jais, Gilles Salles, Hervé Tilly, for the Groupe d’Etude des Lymphomes de l’Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open - label randomised phase 3 trial. Lancet. 2011; 378: 1858-67.
  24. Oki Y., Westin J.R, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister F.B, Mc Laughlin P, Kwak L.W, Romaguera J.E, Fanale M, Younes A, Rodriguez M.A, Orlowski R.Z, Wang M, Ouzounian S.T, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high - dose methotrexate with cytarabine for young patients with high - risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec;163(5):611-20.
  25. Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high - risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011; 96(8).
  26. Chang D.H, Liu N, Klimek V et al. Enhancement of ligand - dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood. 2006;108:618-621.
  27. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327.
  28. Yang Y, Shaffer A.L 3rd, Emre N.C et al: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012; 21:723-737.
  29. Wiernik P.H, Lossos I.S, Tuscano J.M et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008; 26:4952-4957.
  30. Witzig T.E, Vose J.M, Zinzani P.L et al. An International Phase II trial of single - agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011; 22:1622-1627.
  31. Ivanov V, Tabouret E, Chuto G et al. Rituximab - lenalidomide - dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010; 51:1758-1760.
  32. Hernandez-Ilizaliturri F.J, Deeb G, Zinzani P.L, Pileri S.A, Malik F, Macon W.R, Goy A, Witzig T.E, Czuczman M.S. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell - like than in germinal center B-cell - like phenotype. Cancer. 2011 Nov 15;117(22):5058-66.
  33. Zonder J.A, Crowley J, Hussein M.A et al. Lenalidomide and high - dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116(26):5838-5841.
  34. Popat U, Saliba R, Thandi R et al. Impairment of filgrastim induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:718-723.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies